×
Clene Net Cash Flow 2018-2025 | CLNN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Clene net cash flow from 2018 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
View More
Clene Net Cash Flow 2018-2025 | CLNN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Clene net cash flow from 2018 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$231B
Amgen (AMGN)
$161.4B
Gilead Sciences (GILD)
$139.9B
Vertex Pharmaceuticals (VRTX)
$96.3B
Bristol Myers Squibb (BMY)
$93.3B
CSL (CSLLY)
$83.8B
GSK (GSK)
$76.1B
Regeneron Pharmaceuticals (REGN)
$61.5B
Alnylam Pharmaceuticals (ALNY)
$54.9B
Argenex SE (ARGX)
$41.3B
BioNTech SE (BNTX)
$26.7B
Royalty Pharma (RPRX)
$21.3B
Insmed (INSM)
$21.2B
Biogen (BIIB)
$19.5B
Incyte (INCY)
$15.2B
Illumina (ILMN)
$15B
Genmab (GNMSF)
$14.7B
Genmab (GMAB)
$14.2B
BioMarin Pharmaceutical (BMRN)
$11.9B
Ascendis Pharma (ASND)
$11.4B
QIAGEN (QGEN)
$11.1B
Moderna (MRNA)
$10.7B
Swedish Orphan Biovitrum (BIOVF)
$10.6B
Exelixis (EXEL)
$10.1B
Verona Pharma American Depositary Share (VRNA)
$9B
Exact Sciences (EXAS)
$8.9B
Bio-Techne Corp (TECH)
$8.6B
Blueprint Medicines (BPMC)
$8.3B
Roivant Sciences (ROIV)
$7.9B
Halozyme Therapeutics (HALO)
$7.5B